Connection

Laurent Peyrin-Biroulet to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Follow-Up Studies.
Laurent Peyrin-Biroulet
Connection Strength
0.234
Follow-Up Studies
  1. Personalised medicine in inflammatory bowel diseases: a patient survey. Scand J Gastroenterol. 2019 01; 54(1):135.
    View in: PubMed
    Score: 0.050
  2. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
    View in: PubMed
    Score: 0.045
  3. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017 Mar; 49(3):280-285.
    View in: PubMed
    Score: 0.044
  4. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
    View in: PubMed
    Score: 0.013
  5. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
    View in: PubMed
    Score: 0.012
  6. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar; 33(3):664-670.
    View in: PubMed
    Score: 0.012
  7. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018 03; 47(5):588-595.
    View in: PubMed
    Score: 0.012
  8. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2018 06; 16(6):892-899.e2.
    View in: PubMed
    Score: 0.012
  9. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
    View in: PubMed
    Score: 0.011
  10. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 08; 23(8):1425-1433.
    View in: PubMed
    Score: 0.011
  11. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.